Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

The Medicines Co. Pulls European Application For Oritavancin

This article was originally published in The Pink Sheet Daily

Executive Summary

Specialty pharma plans to investigate antibiotic as single-dose, 1,200 mg therapy after FDA and EMEA turned down proposed 200 mg, multi-day dosing.

You may also be interested in...



The Medicines Company CEO Clive Meanwell, An Interview With "The Pink Sheet" DAILY (Part 2 Of 3)

The Medicines Company gradually has revised its business model, moving into earlier-stage research, largely through the acquisition of two biotechs in the past year.

TMC Looks To Add cSSSI Drug, Antibiotic Capabilities With Targanta Offer

Proposed merger would see The Medicines Company take over development of oritavancin, stalled at FDA due to “complete response” letter.

Cancer-Genomics Firm Quanticel Debuts With Close Ties To Celgene, And An Exit In Mind

Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.

Topics

UsernamePublicRestriction

Register

PS069876

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel